Full-Time

Pharmacist

Posted on 11/22/2025

Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

No salary listed

Sheridan, MO, USA

In Person

Category
Medical, Clinical & Veterinary (1)
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Education: Bachelor of Science Degree or Doctor of Pharmacy degree from an accredited School/College of Pharmacy; current, unrestricted pharmacist license through the appropriate state board of pharmacy.
  • Experience: normally requires one (1) to three (3) years of directly related and progressively responsible retail/ambulatory care pharmacy experience.
  • Business/administration knowledge: broad training and/or experience in the fields of business administration, sales, marketing, information technology and retail/ambulatory pharmacy.
  • Skills and abilities: Ability to communicate effectively both orally and in writing; ability to work quickly and accurately under time and volume constraints; strong leadership skills; strong interpersonal skills; ability to resolve patient issues quickly and creatively to improve customer satisfaction; familiarity with pharmaceutical products, services and drug interactions; strong organizational skills; attention to detail; good analytical skills; knowledge of Microsoft Word, Excel, PowerPoint and Outlook; knowledge of the 340b drug program is a plus.
Responsibilities
  • Responsible for evaluating, preparing, and dispensing of medications; verifies prescribed medications according to professional standards, facility procedures, and state and federal legal requirements.
  • Provides excellent customer service and clinical care.
  • Interacts closely with individual patients in order to answer all questions and/or concerns regarding their medication therapy.
  • Reviews and evaluates patient\'s plan of care for therapeutic appropriateness.
  • Consults with prescribers and other medical staff to determine a patient’s appropriate medical/prescription care plan.
  • Participates in achieving business goals and metrics for the ambulatory pharmacy, including assisting in marketing events and promotions.
  • Assists in the fiscal management of the ambulatory pharmacy to optimize profits and control expenses for the ambulatory pharmacy consistently consulting with the other relevant managers and directors.
  • Assists with managing all functions for the ambulatory pharmacy technicians such as hiring, training, and performance management.
  • Monitors the overall performance of all ambulatory pharmacy staff members to ensure compliance with regulatory and organizational policies, practices and approved pharmaceutical dispensing processes.
  • Makes recommendations to the managers regarding any changes to improve operating procedures, or to improve and facilitate patient care.
  • Assists in maintaining and executing all established procedures concerning quality improvement, quality assurance, security of controlled substances, and record keeping.
  • Submits, reviews, and handles all adjudicated prescription claims to ensure appropriateness of reimbursement, co-pay and related financials and, if needed, follows up all such claims deemed inappropriate.
  • Promptly and appropriately responds to patient inquiries, requests and issues when situations are escalated to a higher level of authority. Follows through on closing any outstanding patient concerns to provide a superior level of customer care.
  • Provides consultation on pharmacy and therapeutic matters to various levels of organizational personnel.
  • Assists and reviews daily reporting and scheduling of hours worked for the pharmacy technicians to include sick time, vacation time, personal and holiday time and adjusts scheduling as appropriate to assure optimal patient care is maintained.
  • Supervises activities relative to patient profiles and contacts, ensuring that they are updated as needed for insurance verification and regulatory compliance.
  • Participates in departmental meetings and in-service training for pharmacy technicians.
  • Works collaboratively with organizational personnel on quality, satisfaction, service excellence, clinical care, etc. as needed.
  • Operates the point-of-sale system
  • Performs related duties as assigned.
Desired Qualifications
  • Knowledge of the 340b drug program is a plus

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Simplify Jobs

Simplify's Take

What believers are saying

  • OneOncology $5B acquisition completed December 2025 boosts specialty oncology leadership.
  • EyeSouth retina business $1.1B deal expands Retina Consultants, accretive to EPS post-closure.
  • FY2026 EPS guidance raised to $17.65–$17.90 despite revenue headwinds from biosimilars.

What critics are saying

  • Frank R. Cruz investigation triggers shareholder lawsuits after May 6, 2026 Q2 revenue miss.
  • McKesson and Cardinal Health seize specialty drug share via aggressive GLP-1 pricing.
  • Inflation Reduction Act price cuts compress margins beyond $2B Q2 2026 headwind.

What makes Cencora unique

  • Cencora rebranded from AmerisourceBergen in August 2023, trading as COR on NYSE.
  • Cencora operates 1,400 locations across 50+ countries for global pharmaceutical distribution.
  • Cencora uniquely serves human and animal health with specialty pharmacy and MSO platforms.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 23rd, 2026
Cencora buys EyeSouth Partners' retina business for $1.1B to expand Retina Consultants of America

Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. The affiliated retina physicians will join Cencora's Retina Consultants of America, a leading management services organisation. The pharmaceutical solutions company expects the acquisition to be slightly accretive to its adjusted diluted earnings per share in the first twelve months following closure, net of financing costs. The transaction requires regulatory approvals and customary closing conditions. Cencora's reaffirmed fiscal 2026 financial guidance does not currently include the transaction closing within that fiscal year. BofA Securities served as lead financial advisor to Cencora, whilst Jefferies advised EyeSouth Partners, a portfolio company of Olympus Partners.

The Associated Press
Mar 17th, 2026
Cencora CFO James Cleary to retire after eight years, search underway for successor

Cencora has announced that Chief Financial Officer James F. Cleary will retire effective 30 June 2026. The pharmaceutical solutions company has engaged an executive search firm to identify potential successors from internal and external candidates. Cleary, 62, has served as CFO since November 2018 and joined Cencora in February 2015 following its acquisition of MWI Veterinary Supply, where he had been chief executive officer for over a decade. He will serve in an advisory capacity through the end of 2026 to ensure a smooth transition. Cencora reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal year 2026. The company, ranked number 10 on the Fortune 500, generates more than $300 billion in annual revenue.

TradingView
Feb 11th, 2026
Cencora prices $3B senior notes offering across multiple maturities

Cencora has priced a $3 billion senior notes offering across various maturities, the company announced on 10 February 2026. No further details about the specific maturities, interest rates or intended use of proceeds were disclosed in the announcement.

Yahoo Finance
Feb 4th, 2026
Cencora raises fiscal 2026 guidance after completing OneOncology acquisition

Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.

Yahoo Finance
Feb 4th, 2026
Cencora beats profit estimates on specialty drug demand, completes $5B OneOncology acquisition

Cencora beat Wall Street's first-quarter profit estimates on Wednesday, driven by sustained demand for specialty medicines and GLP-1 therapies. The drug distributor reported adjusted earnings of $4.08 per share, exceeding analysts' expectations of $4.04. The company completed its $5 billion acquisition of OneOncology from TPG in December, strengthening its presence in cancer care. It raised its fiscal 2026 adjusted operating income growth forecast to 11.5% to 13.5%, up from 8% to 10% previously. However, quarterly revenue of $85.93 billion fell short of expectations of $86.03 billion, sending shares down 5% in pre-market trading. Sales at its largest unit, US healthcare solutions, rose 5% year-over-year to $76.2 billion, boosted by prescription volumes of weight-loss drugs and specialty medicines.

INACTIVE